Three months after an FDA approval for cancer immunotherapy Unloxcyt, Checkpoint Therapeutics has found a buyer. | Three ...
India's Sun Pharmaceutical Industries said on Monday it will acquire Checkpoint Therapeutics , a U.S.-based immunotherapy and targeted oncology company, for $355 million.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback